The University of Baghdad is the largest university in Iraq, tenth largest in the Arab world, and the largest university in the Arab world outside Egypt.

During the past decade, University of Baghdad conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "University of Baghdad" are "COVID-19 Pandemic" (1 trials), "Chronic Myeloid Leukemia" (1 trials) and "Periodontal Diseases" (1 trials). Many other conditions were trialed in "University of Baghdad" in a lesser frequency.

Most popular intervention types in "University of Baghdad" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Colchicine 0.5 MG" (1 trials), "HRQOL questionnaire" (1 trials) and "Melatonin 5Mg Oral Tablet" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Baghdad" are 3 trials for "All" genders.

Currently, there are NaN active trials in "University of Baghdad". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in University of Baghdad, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in University of Baghdad, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".